HDLForum

What's New

• Low HDL2 is associated with increased coronary risk
• HDL: possible anti-calcifying effect in aortic valves?
• HDL functionality in high-risk patients at LDL goal
• Emerging therapies: MicroRNAs
• New insights into ABCA1, reverse cholesterol transport and HDL cholesterol
• Isolated low HDL-C increases coronary risk

Viewpoints

Expert Opinion: Focus on HDL

Professor Philip Barter, Director, The Heart Research Institute, Sydney, Australia discusses key issues including:

• Potential role of HDL as a therapeutic target
• HDL and insulin resistance
• Relevance of apoA-I
• Emerging HDL therapies
• Residual cardiovascular risk

Watch the video here

Hot Topic

Managing dyslipidemic patients with the metabolic syndrome - Focus on the HDL-triglyceride axis
A roundtable discussion for HDL Forum held during the European Atherosclerosis Society Congress, 26-29th June, 2011 Gothenburg, Sweden

Outcomes studies with CETP inhibitors - hypothetical discussions

Professor Philip Barter, HDL Forum Editor and Director of The Heart Research Institute, Sydney Australia

Forthcoming Meetings

13-16 March, 2012: 4th International Singapore Lipid Symposium (ISLS)
Singapore
More Information

24-27 March, 2012: ACC12
Chicago, USA
More Information

25-29 March, 2012: XVI International Symposium on Atherosclerosis (ISA2012)
Sydney, Australia
More Information

30 March-1 April 2012: HDL Satellite Symposium 2012
Cairns, Tropical North Queensland, Australia
More Information

18-20 April, 2012: ATVB 2012
Chicago, USA
More Information